This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data supplement
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Cowen, P. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Cowen, P. J.
Advances in Psychiatric Treatment (2005) 11: 19-27
© 2005 The Royal College of Psychiatrists

New drugs, old problems

REVISITING... PHARMACOLOGICAL MANAGEMENT OF TREATMENT-RESISTANT DEPRESSION

Philip J. Cowen

Philip Cowen is Professor of Psychopharmacology at the Warneford Hospital (University Department of Psychiatry, Warneford Hospital, Oxford OX3 7JX. Tel.: 01865 226394; fax: 01865 251076; e-mail: phil.cowen{at}psych.ac.uk). He is also an honorary consultant psychiatrist at the Warneford and a Medical Research Council clinical scientist. His main interest is in the neurobiology of mood disorders and their treatment.

Effective pharmacological management of depression resistant to antidepressant medication is best carried out in the context of a supportive and collaborative relationship, following a mutually agreed care plan. Simpler pharmacological approaches such as switching antidepressant classes are tried first, then augmentation is used if needed. New classes of antidepressants have made antidepressant combination a popular augmentation strategy, but lithium addition has most supporting evidence. The use of atypical antipsychotics as augmenting agents is increasing. For patients unresponsive to these strategies, monoamine oxidase inhibitors and electroconvulsive therapy remain important. Large randomised pragmatic trials are needed to help clinicians and patients make better treatment choices.




This article has been cited by other articles:


Home page
 Adv. Psychiatr. Treat.Home page
A. Kent and T. Burns
Assertive community treatment in UK practice: REVISITING... SETTING UP AN ASSERTIVE COMMUNITY TREATMENT TEAM
Adv. Psychiatr. Treat., November 1, 2005; 11(6): 388 - 397.
[Abstract] [Full Text] [PDF]

Home page
 Adv. Psychiatr. Treat.Home page
N. Seivewright, C. McMahon, and P. Egleston
Stimulant use still going strong: REVISITING... MISUSE OF AMPHETAMINES AND RELATED DRUGS
Adv. Psychiatr. Treat., July 1, 2005; 11(4): 262 - 269.
[Abstract] [Full Text] [PDF]

Home page
 Adv. Psychiatr. Treat.Home page
A. M. Mortimer
Another triumph of hope over experience?: REVISITING... TREATMENT OF THE PATIENT WITH LONG-TERM SCHIZOPHRENIA
Adv. Psychiatr. Treat., July 1, 2005; 11(4): 277 - 285.
[Abstract] [Full Text] [PDF]

Home page
 Adv. Psychiatr. Treat.Home page
A. Lee
Ten years of APT
Adv. Psychiatr. Treat., January 1, 2005; 11(1): 1 - 3.
[Full Text] [PDF]

Home page
 Adv. Psychiatr. Treat.Home page
K. Gournay
The changing face of psychiatric nursing: REVISITING... MENTAL health nursing
Adv. Psychiatr. Treat., January 1, 2005; 11(1): 6 - 11.
[Abstract] [Full Text] [PDF]